John M. Conley

Learn More
Sole-source business models for genetic testing can create private databases containing information vital to interpreting the clinical significance of human genetic variations. But incomplete access to those databases threatens to impede the clinical interpretation of genomic medicine. National health systems and insurers, regulators, researchers, providers(More)
by John M. Conley Author(s): Sally Engle Merry Reviewed work(s): Source: Current Anthropology, Vol. 52, No. S3, Corporate Lives: New Perspectives on the Social Life of the Corporate Form: Edited by Damani J. Partridge, Marina Welker, and Rebecca Hardin (Supplement to April 2011), pp. S83-S95 Published by: The University of Chicago Press on behalf of(More)
Genomic biobanks present ethical challenges that are qualitatively unique and quantitatively unprecedented. Many critics have questioned whether the current system of informed consent can be meaningfully applied to genomic biobanking. Proposals for reform have come from many directions, but have tended to involve incremental change in current informed(More)
Myriad Genetics' long-time monopoly on BRCA gene testing was significantly narrowed by the Supreme Court's decision in AMP v. Myriad Genetics, Inc., and will be further narrowed in the next few years as many of its still-valid patents expire. But these developments have not caused the company to acquiesce in competition. Instead, it has launched a(More)
ideas such as mathematical algorithms have historically been deemed nonstatutory (Diamond v. Chakrabavty, 447 U.S. 303 [1980]). Second, the claimed invention must be novel. Novelty has a highly technical meaning, which is articulated in the complex provisions of Section 102 of the Patent Act. For example, under Section 102(a), the patent will be denied if(More)
In this fictional case study, Adam Lawson is a promising young associate at Kirkham McDowell Securities, a St. Louis underwriting and financial advisory firm. Recently, Adam helped to bring in an extremely lucrative deal, and soon he and a few other associates will be honored for their efforts at the firm's silver anniversary dinner. George Campbell, vice(More)
To cite this article: Gabriel Lázaro-Muñoz, John M. Conley, Arlene M. Davis, Marcia Van Riper, Rebecca L. Walker & Eric T. Juengst (2015) Response to Open Peer Commentaries on “Looking for Trouble: Preventive Genomic Sequencing in the General Population and the Role of Patient Choice”, The American Journal of Bioethics, 15:12, W6-W9, DOI:(More)
As a result of the expanded use of health-related quality of life (HRQL) measures in clinical trial research, a variety of legal and ethical issues have surfaced. These issues can be put in the form of the following questlons: (1) Under what circumstances should access to HRQL measures be restricted? (2) Under what circumstances is it appropriate for the(More)